Discovering Noxopharm And 2 Other ASX Penny Stocks To Watch
In This Article:
The Australian market remained flat over the last week but has seen a 22% increase over the past year, with earnings forecasted to grow by 12% annually. For investors interested in smaller or newer companies, penny stocks—despite their somewhat outdated moniker—can still present valuable opportunities. These stocks often offer a mix of affordability and growth potential when backed by strong financials, making them worth watching for those seeking underappreciated chances for growth.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Financial Health Rating |
| LaserBond (ASX:LBL) | A$0.57 | A$65.06M | ★★★★★★ |
| Embark Early Education (ASX:EVO) | A$0.795 | A$128.44M | ★★★★☆☆ |
| MaxiPARTS (ASX:MXI) | A$1.825 | A$104.82M | ★★★★★★ |
| Austin Engineering (ASX:ANG) | A$0.50 | A$310.07M | ★★★★★☆ |
| Helloworld Travel (ASX:HLO) | A$1.85 | A$300.41M | ★★★★★★ |
| Navigator Global Investments (ASX:NGI) | A$1.70 | A$842.94M | ★★★★★☆ |
| West African Resources (ASX:WAF) | A$1.715 | A$1.95B | ★★★★★★ |
| Atlas Pearls (ASX:ATP) | A$0.135 | A$56.64M | ★★★★★★ |
| GTN (ASX:GTN) | A$0.47 | A$92.11M | ★★★★★★ |
| Joyce (ASX:JYC) | A$3.90 | A$115.92M | ★★★★★★ |
Click here to see the full list of 1,027 stocks from our ASX Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Noxopharm
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Noxopharm Limited is an Australian biotech company focused on discovering and developing treatments for cancer, inflammation, and mRNA vaccines, with a market cap of A$33.61 million.
Operations: The company generates revenue of A$2.40 million from its development activities in both oncology and non-oncology fields.
Market Cap: A$33.61M
Noxopharm Limited, with a market cap of A$33.61 million, is pre-revenue, generating only A$2.40 million from its development activities in oncology and non-oncology fields. The company has no debt and a cash runway exceeding three years based on current free cash flow levels. Despite being unprofitable with a negative return on equity of -65.11%, it has an experienced management team and board of directors with average tenures of 3.8 and 4.6 years respectively. Recent earnings results showed an improved net loss of A$3.58 million compared to the previous year's A$15.06 million loss, indicating progress in financial performance despite high share price volatility.
Qualitas
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Qualitas (ASX:QAL) is a real estate investment firm engaged in direct investments across various real estate classes and geographies, as well as acquisitions, distressed debt restructuring, third-party capital raisings, and consulting services, with a market cap of A$755.31 million.